Our CEO, Beth Hoffman, participated in a very successful panel on the progress being made to develop new therapeutics for neurodegenerative diseases at the BIO Investor Forum. Some of her thoughts are highlighted in this summary. https://lnkd.in/gfRfxpvk
Origami Therapeutics, Inc.
生物技术研究
San Diego，California 1,872 位关注者
Developing curative medicines for neurodegenerative diseases
关于我们
Origami Therapeutics is a preclinical-stage company developing novel protein degrader therapeutics with a proprietary drug discovery platform which holds the promise for disease-modification in neurodegenerative diseases such as Huntington’s Disease. We are pioneering the next-generation of small molecules targeting disease-causing proteins. At Origami Therapeutics, we’re leading the creation of an entirely new way to treat disease through therapies that target and degrade disease-related proteins. We are a preclinical-stage biopharmaceutical company focused on developing new therapeutics for neurodegenerative diseases, beginning with Huntington’s Disease. Our proprietary protein degraders work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins. We have built upon groundbreaking research of our founder Beth Hoffman, a veteran drug discovery scientist who discovered transformational therapeutics for cystic fibrosis. Origami is developing a broad technology platform focused on high-value targets, with the potential to deliver more potent therapies and to address the >80% of proteins that evade inhibition and have been “undruggable” by traditional approaches. Our lead programs are focused on neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD) and Huntington’s disease (HD). Our hope is to unlock the full potential of ORIGAMI protein degradation by developing our own robust pipeline and by partnering with the world’s leading drug development companies.
- 网站
-
https://www.origamitherapeutics.com
Origami Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- San Diego，California
- 类型
- 私人持股
- 创立
- 2016
- 领域
- biotechnology、neurology和drug development
地点
-
主要
获取路线
10210 Campus Point Dr
Suite 150
US，California，San Diego，92121
Origami Therapeutics, Inc.员工
动态
-
It has been a real pleasure working with the incredible O2h team. Their help and support has been critical to our success.
#SuccessStory Two years ago, we launched the o2h Kickstarter program with the aim of empowering biotech startups at crucial moments in their drug discovery journey. We’re pleased to have supported more than ???? innovative biotech startups all over the world, helping them progress their novel drug development and beyond. One of our standout success stories is that of Origami Therapeutics, Inc., whose groundbreaking work in the initial phase of structure-activity relationship (SAR) studies has gained momentum. Becoming a Kickstarter winner gave them access to vital chemistry resources, project management support, and a network that helped them advance from concept to tangible progress. Since then, Origami Therapeutics has moved forward in drug discovery by identifying new therapeutic candidates and attracting industry attention. ?? Recently, Origami Therapeutics was recognized as one of the top 100 biotech startups funded by Y Combinator. This recognition further highlights the progress they’ve made, showcasing how strategic support, like that from the o2h Kickstarter program, can accelerate early-stage growth. You can read more about their journey here: https://lnkd.in/gYUbJzcY Their story is an example of how the right support at the right time can make a difference. We’re proud to have played a small part in Origami’s journey and remain committed to nurturing the next wave of biotech innovators. We recently launched the latest edition of ?????? ??????????????????????: ???????????????? ?????????????? to further support USA-based biotech start-ups. If you want to maximise this opportunity, visit https://lnkd.in/dAxrjKjn?or write to us at [email protected] #BiotechInnovation #DrugDiscovery #StartupSuccess #SeedingNewIdeas #Biotech #o2hKickstarter #InnovateAmerica #SmallMolecule #EarlyStage #USAStartups #Biotech
-
-
Our CEO, Beth J Hoffman, is interviewed by Partnology this week.
Please join us in recognizing Beth J Hoffman, Founder and CEO of Origami Therapeutics, Inc., in this weeks Biotech Leader Spotlight Series! Beth brings more than 25 years of #CNS drug discovery experience and has developed over 30 assets that have advanced into the clinic in cystic #fibrosis, #metabolic diseases, #neurology, #pain and #psychiatry. Prior to Origami, she was Vice President, Discovery Biology for Vertex Pharmaceuticals, where she generated and launched clinical candidates for #respiratory and #neurological diseases, including first-in-class blockbuster drugs in cystic fibrosis (Kalydeco, Orkambi, Symdeko, Trikafta). She expanded the market for Orkambi and increased sales to over $1 billion, and also generated a novel non-opioid pain #therapeutic and other protein folding programs at Vertex. Dr. Hoffman received an A.B. in Molecular Biology from Wellesley College and a Ph.D. in Cell Biology from The Johns Hopkins University. She is a member of the Board of Trustees for the Huntington's Disease Society of America as well as a Scientific Advisor for the Tau Consortium of the The Rainwater Charitable Foundation, focusing on alleviating diseases associated with tau #pathology, such as Alzheimer’s Disease. She is also on the Board of Biofrontera Inc. #biotechleader #womeninbio #womeninscience #femaleleaders #biotechexecutive #biotechfounder #biotech #biotechnology #drugdevelopment #drugdiscovery #therapeutics #biopharma
Biotech Leader Spotlight Series
Partnology，发布于领英
-
NuFund Releases its 2023 Annual Report: Strategic Investments and High-Impact Exits Highlight Success - https://lnkd.in/ecWSi--k Follow Citybiz on LinkedIn - https://lnkd.in/gStBXi2X Ashok Kamal, Serhat Pala, NuFund Venture Group, Dean Rosenberg, Heather Slotnick, Kate Dilligan, Aurenar, Inc, Cayuga Biotech, CorralData, Ecodrive, Eyegenex, ICHOR Vascular Inc., Kneevoice Inc., LIMBER Prosthetics and Orthotics, Neuralace Medical, Ordaos Bio, Origami Therapeutics, Inc., Papillon Therapeutics, PercAssist, Inc, SIRPant Immunotherapeutics #citybiz #citybiznews #SanDiegoAI #SanDiegoStartup #AIrevolution #DigitalHealth #GlobalTech #NuFundInnovation #BusinessConsulting #technology #innovation #Tech #investment #investing #California #entrepreneurs #investments #angelinvestors #fund #venturecapital #investors #report #annualreport #strategicinvestments?
-
-
Digital Therapeutics Market?Size to Hit US$?21.9 billion by 2028 ???????????????? ???????? ???????????? ??????????:https://lnkd.in/dSjg6dmW The digital therapeutics market is projected to reach USD 21.9 billion by 2028 from USD 6.1 billion in 2023, at a CAGR of 29.1% during the forecast period ?????? ?????????????????? ???????????????? ???? ???????? ???????????? ?????????????? Noom, Inc?(US),?Teladoc Health, Inc.?(US),?Omada Health, Inc.?(US),?WellDoc, Inc?(US),?Biofourmis?(US), Better Therapeutics, Inc (US),?Amalgm Rx?(US),?CogniFit Inc?(US),?Headspace Health?(US),?Propeller Health?(US),?Virta Health Corp?(US),?2Morrow, Inc.?(US),?Realizedcare?(US),?Canary Health?(US),?Twill Inc.?(US),?Click Therapeutics, Inc.?(US),?Akili, Inc.?(US),?Cognoa, Inc?(US),?Wellthy Therapeutics Pvt. Ltd.?(India),?Kaia Health?(Germany),?Ayogo?(Canada), Mindable Health GmbH (Germany),?Hinge Health, Inc.?(US), and?Freespira?(US). ?????????? ?????????????????? ?????????????????? ???? ???????? ???????????? ???????????????? Kopra Bio ParcelBio Granza Bio (YC W24) Junction Bioscience ēvolvere Biosciences Eris Biotech (YC W24) Velorum Therapeutics (YC W24) SynsoryBio Modulari-T Bio Guardian Bio Relevium Medical Serinus Biosciences Eugit Therapeutics Origami Therapeutics, Inc. Alixia Engage Bio Keylika (YC S22) SFA Therapeutics Output Biosciences Sensible Biotechnologies Humane Genomics Inflow Promakhos Therapeutics PipeBio Nuntius Therapeutics Biodock Valink Therapeutics Serna Bio Nephrogen
-
-
Very happy to have the support of the NINDS Small Business Programs which has significantly helped the advancement of our program. Beth J Hoffman
Congratulations to Origami Therapeutics, Inc.. on their recent #SBIR Phase I?award. Their project is entitled "Characterization of small molecules that lower mutant huntingtin protein as potential therapeutics for Huntington’s disease". Normal #huntingtin protein (HTT) is essential throughout the body and brain to regulate cell physiology. In patients with #Huntington’sdisease (#HD), mutant HTT (mHTT) folds abnormally, resulting in toxic mHTT fragments. Experimental procedures that lower mHTT have reversed disease symptoms in animal models of HD. However, clinical translation of treatments directed at this mechanism of action have stalled and is, in part, hypothesized to be due to nonselective lowering of both the essential HTT as well as mHTT.?Origami Therapeutics has identified a small molecule, #ORI113, that prevents mHTT aggregation, and selectively lowers mHTT levels in assays employing HD patient-derived fibroblasts and iPSC-derived medium spiny neurons as well as the #YAC128 mouse model of HD. The efficacy and drug-like properties of twelve analogs of ORI-113 will be compared and lead compounds will undergo #pharmacokinetic and #brainexposure profiling following oral administration. The studies aim to identify a lead therapeutic drug candidate to move into Investigational New Drug Application studies.?
-
-
The best way we learn is by “getting out of the building.” ? Our CEOs Philipp Baaske and Stefan Duhr recently had the privilege of meeting with researchers, fellow CEOs, and our customers throughout the United States. These exchanges drive our vision: to help create a world where every disease is treatable.? ?? Thank you to everyone who took the time to share their thoughts, experiences, and projects: Flavia Nachbar (MBC BioLabs), James Inglese and Anton Simeonov (National Center for Advancing Translational Sciences (NCATS), Andrey Bobkov (Sanford Burnham Prebys), Beth J Hoffman (Origami Therapeutics, Inc.), Mauro Mileni (Abilita Therapeutics, Inc.), Devon Cayer (om) and more! ? Your insights and feedback help us grow and innovate, ensuring we can serve our customers better every day.
-
-
Our CEO, Beth J Hoffman will be moderating an outstanding panel of entrepreneurs, asking them to share the trials and tribulations of raising money in the current environment. Join us!
Join #SDEE for “Strategies for #Founders #Fundraising” on May 16, 5-7:30 pm at Green Acre Campus Point. Beth J Hoffman from Origami Therapeutics, Inc. will moderate an all-founder panel with Mauro Mileni of Abilita Therapeutics, Inc., Devon Cayer of om, and Philipp Baaske of NanoTemper Technologies. Register at https://lnkd.in/dYSYccRi Janelle Hunt Marilyn Ferrari Danielle Hayes Randy Schreckhise Taylor Moyer Ted Jacobs Jim Krenn Jiwu Wang R Scott Struthers Scott Thacher Kathrin Copley Lynda Groocock Lecya Tyaglo Richard Lin Ruo Steensma Martin Eglitis
-